Senores Pharmaceuticals Ltd Schedules Board Meeting to Approve Q1 FY27 Financial Results
Senores Pharmaceuticals Limited has scheduled a meeting of its Board of Directors to consider and approve the Unaudited Consolidated and Standalone Financial Results for the quarter ended June 30, 2026. The meeting is set to take place on Monday, July 27, 2026, where other business matters will also be transacted.The Board meeting is intended to address the financial performance of the Company for the specified quarter and conduct other necessary business activities.
In connection with the financial results, previous information was provided regarding the trading window for persons specified under the Code. This trading window was closed starting July 01, 2026, and will remain closed until 48 hours following the approval of the Unaudited Consolidated and Standalone Financial Results by the Board of Directors and their subsequent submission to Stock Exchanges.
SENORES Stock Price Movement
Senores Pharmaceuticals Limited shares closed today after edging higher by 1.38%, settling at ₹1404. The stock experienced robust intraday trading, which saw it fluctuate between a low of ₹1368.7 and a high of ₹1410, with a volume of 130,976 shares exchanged.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.